Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl) -2-hydroxypropyl]-pyrrolidin-2-one derivatives with anti-arrhythmic, hypotensive, and α-adrenolytic activity

Archiv der Pharmazie

Volumn 340, Issue 9, 2007, Pages 466-475

  Kulig, Katarzyna ^a   Sapa, Jacek ^a   Maciag, Dorota ^a   Filipek, Barbara ^a   Malawska, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

adrenoceptor blocking activity; 1 3 (4 arylpiperazin 1 yl) 2 hydroxypropyl pyrrolidin 2 one derivatives; Antiarrhythmic; Hypotensive activity; Molecular modeling

Indexed keywords

1 [2 HYDROXY 3 (2 PHENYLAMINOETHYL)AMINOPROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 (4 2 TOLYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (2 HYDROXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (2 ISOPROPOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (2 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (3 HYDROXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (4 HYDROXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 HYDROXY 3 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [2 METHOXY 3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]PYRROLIDIN 2 ONE; 1 [3 [4 (2 ETHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [3 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL] 2 HYDROXYPROPYL]PYRROLIDIN 2 ONE; 1 [3 [4 (2,4 DIFLUOROPHENYL)PIPERAZIN 1 YL]PROPYL]PYRROLIDIN 2 ONE; 1 [3 [4 (4 CHLORO 2 METHOXYPHENYL)PIPERAZIN 1 YL] 2 HYDROXYPROPYL]PYRROLIDIN 2 ONE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; FLUORINE; METHOXAMINE; METHOXYFLURANE; NORADRENALIN; PIPERAZINE DERIVATIVE; PROPRANOLOL DERIVATIVE; PYRROLIDINE DERIVATIVE; TOLAZOLINE; TYRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG SYNTHESIS; HEART ARRHYTHMIA; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG INTERACTIONS; MALE; MODELS, MOLECULAR; PYRROLIDINONES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34748813245     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700039     Document Type: Article

References (30)

1. K.-E. Anderson, World J. Urol. 2002, 19, 390-396.
2. M. Thiyagarajan, Pharmacology 2002, 65, 119-128.
3. K. Kulig, B. Malawska, Curr. Med. Chem. 2006, 13, 3395-3416.
4. M. G. Bock, M. Patane, Ann. Rep. Med. Chem. 2000, 35, 221-230.
5. J. B. Bremner, R. Griffith, B. Coban, Curr. Med. Chem. 2001, 8, 607-620.
6. M. A. H. Ismail, M. N. Y. Aboul-Enein, K. A. M. Abuzid, R. A. T. Serya, Bioorg. Med. Chem. 2006, 14, 898-910.
7. M.-Y. Li, K.-C. Tsai, L. Xia, Biorg. Med. Chem. Lett. 2005, 15, 657-664.
8. R. M. De Marinis, M. Wise, J. P. Hielbe, R. R. Ruffolo Jr. in The Alpha-1 Adrenergic Receptor (Ed.: R. R. Ruffolo), Humana Press, Clifton, NJ, USA. 1987, pp. 211-265.
9. F. Manetti, F. Corelli, G. Strappaghetti, M. Botta, Curr. Med. Chem. 2002, 9, 1303-1321.
10. E. Patane, V. Pittalla, F. Guerrera, L. Salerno, et al., J. Med. Chem. 2005, 48, 2420-2431.
11. L. Betti, M. Zanelli, G. Giannaccini, F. Manetti, et al., Bioorg. Med. Chem. 2006, 14, 2828-2836.
12. L. Betti, F. Corelli, M. Floridi, G. Giannaccini, et al., J. Med. Chem. 2003, 46, 3555-3558.
13. B. Filipek, J. Sapa, B. Malawska, K. Kulig, L. Antkiewicz-Michaluk, Arch. Pharm. Pharm. Med. Chem. 1997, 330, 225-231.
14. B. Malawska, K. Kulig, B. Filipek, J. Sapa, et al., Eur. J. Med. Chem. 2002, 37, 183-195.
15. B. Malawska, K. Kulig, A. Gippert, B. Filipek, et al., Il Farmoco 2005, 60, 793-803.
16. B. Malawska, M. Gorczyca, B. Cebo, J. Krupinska, Pol. J. Pharmacol. Pharm. 1988, 40, 173-181.
17. R. Ratouis, J. R. Boissier, C. Dumont J. Med. Chem. 1965, 8, 104-107.
18. K. Kiec-Kononowicz, X. Ligneau, J.-Ch. Schwarz, W. Schunack, Arch. Pharm. Pharm. Med. Chem. 1995, 328, 469-472.
19. J. Maj, V. Klimek, G. Nowak, J. Pharmacol 1985, 119, 113-116.
20. Y. C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.
21. O. E. Brodde, H. Bruck, K. Leineweber, J. Pharmacol. Sci. 2006, 100, 323-337.
22. M. T. Piascik, E. E. Soltis, M. M. Piascik, L. B. Macmillan, Pharmacol. Ther. 1996, 72, 215-241.
23. M. Maze, C. M. Smith, Anesthesiology 1983, 59, 322-328.
24. G. E. Billman, J. Cardiovasc. Pharmacol. 1994, 24, 394-400.
25. T. Kurz, K. A. Yamada, S. D. DaTorre, P. B. Corr, Eur. Heart J. 1991, 12 (suppl. F), 88-98.
26. P. B. Corr, G. P. Heathers, K. A. Yamada, Am. J. Med. 1989, 87 (suppl. 2A), 19S-25S.
27. G. E. Billman, J. Pharmacol. Exp. Ther. 1994, 269, 409-416.
28. L. Szekeres, G. Papp in Handbook of Experimantal Pharmacology (Eds.: J. Schmier, O. Eichler), Springer Verlag, Berlin, Heidelberg, New York, 1975.
29. CAChe Work System Pro Version 5.04.
30. M. J. Walker, M. J. Curtis, D. J. Hearse, R. W. Campbell, et al., Cardiovasc Res. 1988, 22, 447-455.